Overview

An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Status:
NOT_YET_RECRUITING
Trial end date:
2029-10-10
Target enrollment:
Participant gender:
Summary
Study GB3226-DEV-001 is a Phase 1/2, open-label, dose-escalation and expansion study of GB3226 in the treatment of relapsed or refractory acute myeloid leukaemia
Phase:
PHASE1
Details
Lead Sponsor:
Galecto Biotech AB